Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a "P301L" tau knockin mouse

Neurobiology of Aging

Volumn 33, Issue 3, 2012, Pages 621.e1-621.e15

  Gilley, Jonathan ^a   Seereeram, Anjan ^b   Ando, Kunie ^c   Mosely, Suzanne ^a   Andrews, Simon ^a   Kerschensteiner, Martin ^d   Misgeld, Thomas ^e   Brion, Jean Pierre ^c   Anderton, Brian ^b   Hanger, Diane P ^b   Coleman, Michael P ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d UNIVERSITY OF MUNICH   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Axonal transport; FTDP 17T; Knockin mouse; Mitochondria; P301L mutation; Tau

Indexed keywords

PROTEIN P30; TAU PROTEIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME 17; COGNITION; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HOMOZYGOSITY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MICROTUBULE; MITOCHONDRION; MOUSE; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NONHUMAN; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE;

EID: 84855815656     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.02.014     Document Type: Article

References (80)

1. Adams S.J., Crook R.J., Deture M., Randle S.J., Innes A.E., Yu X.Z., Lin W.L., Dugger B.N., McBride M., Hutton M., Dickson D.W., McGowan E. Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration. Am. J. Pathol 2009, 175:1598-1609.
2. Ahlijanian M.K., Barrezueta N.X., Williams R.D., Jakowski A., Kowsz K.P., McCarthy S., Coskran T., Carlo A., Seymour P.A., Burkhardt J.E., Nelson R.B., McNeish J.D. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2910-2915.
3. Alonso A.C., Zaidi T., Grundke-Iqbal I., Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:5562-5566.
4. Ando K., Leroy K., Heraud C., Yilmaz Z., Authelet M., Suain V., De Decker R., Brion J.P. Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am J Pathol 2011, 178:803-816.
5. Andorfer C., Kress Y., Espinoza M., de Silva R., Tucker K.L., Barde Y.A., Duff K., Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem 2003, 86:582-590.
6. Andreadis A., Brown W.M., Kosik K.S. Structure and novel exons of the human tau gene. Biochemistry 1992, 31:10626-10633.
7. Andrews S., Gilley J., Coleman M.P. Difference Tracker: ImageJ plugins for fully automated analysis of multiple axonal transport parameters. J. Neurosci. Methods 2010, 193:281-287.
8. Baas P.W., Vidya Nadar C., Myers K.A. Axonal transport of microtubules: the long and short of it. Traffic 2006, 7:490-498.
9. Barghorn S., Zheng-Fischhöfer Q., Ackmann M., Biernat J., von Bergen M., Mandelkow E.M., Mandelkow E. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry 2000, 39:11714-11721.
10. Boekhoorn K., Terwel D., Biemans B., Borghgraef P., Wiegert O., Ramakers G.J., de Vos K., Krugers H., Tomiyama T., Mori H., Joels M., van Leuven F., Lucassen P.J. Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy. J. Neurosci 2006, 26:3514-3523.
11. Brion J.P., Couck A.M., Robertson J., Loviny T.L., Anderton B.H. Neurofilament monoclonal antibodies RT97 and 8D8 recognize different modified epitopes in paired helical filament-tau in Alzheimer's disease. J. Neurochem 1993, 60:1372-1382.
12. Brion J.P., Tremp G., Octave J.N. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. Am. J. Pathol 1999, 154:255-270.
13. Brunden K.R., Zhang B., Carroll J., Yao Y., Potuzak J.S., Hogan A.M., Iba M., James M.J., Xie S.X., Ballatore C., Smith A.B., Lee V.M., Trojanowski J.Q. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J. Neurosci 2010, 30:13861-13866.
14. Bunker J.M., Kamath K., Wilson L., Jordan M.A., Feinstein S.C. FTDP-17 mutations compromise the ability of tau to regulate microtubule dynamics in cells. J. Biol. Chem 2006, 281:11856-11863.
15. Cho J.H., Johnson G.V. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J. Neurochem 2004, 88:349-358.
16. Chohan M.O., Haque N., Alonso A., El-Akkad E., Grundke-Iqbal I., Grover A., Iqbal K. Hyperphosphorylation-induced self assembly of murine tau: a comparison with human tau. J. Neural Transm 2005, 112:1035-1047.
17. Cruz J.C., Tseng H.C., Goldman J.A., Shih H., Tsai L.H. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003, 40:471-483.
18. Cuchillo-Ibanez I., Seereeram A., Byers H.L., Leung K.Y., Ward M.A., Anderton B.H., Hanger D.P. Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J 2008, 22:3186-3195.
19. Davis D.R., Brion J.P., Couck A.M., Gallo J.M., Hanger D.P., Ladhani K., Lewis C., Miller C.C., Rupniak T., Smith C., et al. The phosphorylation state of the microtubule-associated protein tau as affected by glutamate, colchicine and beta-amyloid in primary rat cortical neuronal cultures. Biochem. J 1995, 309:941-949.
20. De Vos K.J., Grierson A.J., Ackerley S., Miller C.C. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci 2008, 31:151-173.
21. Denk F., Wade-Martins R. Knock-out and transgenic mouse models of tauopathies. Neurobiol. Aging 2009, 30:1-13.
22. Ding H., Matthews T.A., Johnson G.V. Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J. Biol. Chem 2006, 281:19107-19114.
23. Dixit R., Ross J.L., Goldman Y.E., Holzbaur E.L. Differential regulation of dynein and kinesin motor proteins by tau. Science 2008, 319:1086-1089.
24. Drechsel D.N., Hyman A.A., Cobb M.H., Kirschner M.W. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 1992, 3:1141-1154.
25. Drewes G., Trinczek B., Illenberger S., Biernat J., Schmitt-Ulms G., Meyer H.E., Mandelkow E.M., Mandelkow E. Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. J. Biol. Chem 1995, 270:7679-7688.
26. Duff K., Knight H., Refolo L.M., Sanders S., Yu X., Picciano M., Malester B., Hutton M., Adamson J., Goedert M., Burki K., Davies P. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis 2000, 7:87-98.
27. Ebneth A., Godemann R., Stamer K., Illenberger S., Trinczek B., Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J. Cell Biol 1998, 143:777-794.
28. Feng G., Mellor R.H., Bernstein M., Keller-Peck C., Nguyen Q.T., Wallace M., Nerbonne J.M., Lichtman J.W., Sanes J.R. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2000, 28:41-51.
29. Götz J., Chen F., Barmettler R., Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem 2001, 276:529-534.
30. Götz J., Probst A., Spillantini M.G., Schäfer T., Jakes R., Bürki K., Goedert M. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 1995, 14:1304-1313.
31. Hanger D.P., Betts J.C., Loviny T.L., Blackstock W.P., Anderton B.H. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem 1998, 71:2465-2476.
32. Hanger D.P., Byers H.L., Wray S., Leung K.Y., Saxton M.J., Seereeram A., Reynolds C.H., Ward M.A., Anderton B.H. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem 2007, 282:23645-23654.
33. Hasegawa M., Smith M.J., Goedert M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett 1998, 437:207-210.
34. Hempen B., Brion J.P. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J. Neuropathol. Exp. Neurol 1996, 55:964-972.
35. Hong M., Zhukareva V., Vogelsberg-Ragaglia V., Wszolek Z., Reed L., Miller B.I., Geschwind D.H., Bird T.D., McKeel D., Goate A., Morris J.C., Wilhelmsen K.C., Schellenberg G.D., Trojanowski J.Q., Lee V.M. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998, 282:1914-1917.
36. Ikegami S., Harada A., Hirokawa N. Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci. Lett 2000, 279:129-132.
37. Ishihara T., Hong M., Zhang B., Nakagawa Y., Lee M.K., Trojanowski J.Q., Lee V.M. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999, 24:751-762.
38. Ittner L.M., Fath T., Ke Y.D., Bi M., van Eersel J., Li K.M., Gunning P., Gotz J. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15997-16002.
39. Kampers T., Pangalos M., Geerts H., Wiech H., Mandelkow E. Assembly of paired helical filaments from mouse tau: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease. FEBS Lett 1999, 451:39-44. [PubMed: 10356980]. 10.1016/S0014-5793(99)00522-0.
40. Köntgen F., Süss G., Stewart C., Steinmetz M., Bluethmann H. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int. Immunol 1993, 5:957-964.
41. Korhonen P., van Groen T., Thornell A., Kyrylenko S., Soininen M.L., Ojala J., Peltomaa E., Tanila H., Salminen A., Mandelkow E.M., Soininen H. Characterization of a novel transgenic rat carrying human tau with mutation P301L. Neurobiol Aging 2010, 10.1016/j.neurobiolaging.2009.12.022.
42. Leroy K., Bretteville A., Schindowski K., Gilissen E., Authelet M., De Decker R., Yilmaz Z., Buée L., Brion J.P. Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am. J. Pathol 2007, 171:976-992.
43. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet 2000, 25:402-405.
44. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
45. Liou Y.C., Sun A., Ryo A., Zhou X.Z., Yu Z.X., Huang H.K., Uchida T., Bronson R., Bing G., Li X., Hunter T., Lu K.P. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 2003, 424:556-561.
46. McTighe S.M., Mar A.C., Romberg C., Bussey T.J., Saksida L.M. A new touchscreen test of pattern separation: effect of hippocampal lesions. Neuroreport 2009, 20:881-885.
47. Merrick S.E., Trojanowski J.Q., Lee V.M. Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons. J. Neurosci 1997, 17:5726-5737.
48. Misgeld T., Kerschensteiner M., Bareyre F.M., Burgess R.W., Lichtman J.W. Imaging axonal transport of mitochondria in vivo. Nat. Methods 2007, 4:559-561.
49. Morais V.A., De Strooper B. Mitochondria dysfunction and neurodegenerative disorders: cause or consequence. J. Alzheimers Dis. 2010, 20(Suppl 2):S255-S263.
50. Morfini G., Pigino G., Mizuno N., Kikkawa M., Brady S.T. Tau binding to microtubules does not directly affect microtubule-based vesicle motility. J. Neurosci. Res 2007, 85:2620-2630.
51. Murakami T., Paitel E., Kawarabayashi T., Ikeda M., Chishti M.A., Janus C., Matsubara E., Sasaki A., Kawarai T., Phinney A.L., Harigaya Y., Horne P., Egashira N., Mishima K., Hanna A., Yang J., Iwasaki K., Takahashi M., Fujiwara M., Ishiguro K., Bergeron C., Carlson G.A., Abe K., Westaway D., St George-Hyslop P., Shoji M. Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation. Am. J. Pathol 2006, 169:1365-1375.
52. Nagiec E.W., Sampson K.E., Abraham I. Mutated tau binds less avidly to microtubules than wildtype tau in living cells. J. Neurosci. Res 2001, 63:268-275.
53. Noble W., Hanger D.P., Gallo J.M. Transgenic mouse models of tauopathy in drug discovery. CNS Neurol. Disord. Drug Targets 2010, 9:403-428.
54. Pennanen L., Welzl H., D'Adamo P., Nitsch R.M., Götz J. Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. Neurobiol. Dis 2004, 15:500-509.
55. Pennanen L., Wolfer D.P., Nitsch R.M., Götz J. Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice. Genes Brain Behav 2006, 5:369-379.
56. Probst A., Gotz J., Wiederhold K.H., Tolnay M., Mistl C., Jaton A.L., Hong M., Ishihara T., Lee V.M., Trojanowski J.Q., Jakes R., Crowther R.A., Spillantini M.G., Burki K., Goedert M. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol 2000, 99:469-481.
57. Ramsden M., Kotilinek L., Forster C., Paulson J., McGowan E., SantaCruz K., Guimaraes A., Yue M., Lewis J., Carlson G., Hutton M., Ashe K.H. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci 2005, 25:10637-10647.
58. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
59. Sato-Harada R., Okabe S., Umeyama T., Kanai Y., Hirokawa N. Microtubule-associated proteins regulate microtubule function as the track for intracellular membrane organelle transports. Cell Struct. Funct 1996, 21:283-295.
60. Scattoni M.L., Gasparini L., Alleva E., Goedert M., Calamandrei G., Spillantini M.G. Early behavioural markers of disease in P301S tau transgenic mice. Behav. Brain Res 2010, 208:250-257.
61. Seitz A., Kojima H., Oiwa K., Mandelkow E.M., Song Y.H., Mandelkow E. Single-molecule investigation of the interference between kinesin, tau and MAP2c. EMBO J 2002, 21:4896-4905.
62. Sengupta A., Kabat J., Novak M., Wu Q., Grundke-Iqbal I., Iqbal K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys 1998, 357:299-309.
63. Specht C.G., Schoepfer R. Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci 2001, 2:11.
64. Specht C.G., Schoepfer R. Deletion of multimerin-1 in alpha-synuclein-deficient mice. Genomics 2004, 83:1176-1178.
65. Spillantini M.G., Crowther R.A., Kamphorst W., Heutink P., van Swieten J.C. Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau. Am. J. Pathol 1998, 153:1359-1363.
66. Stoothoff W., Jones P.B., Spires-Jones T.L., Joyner D., Chhabra E., Bercury K., Fan Z., Xie H., Bacskai B., Edd J., Irimia D., Hyman B.T. Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport. J. Neurochem 2009, 111:417-427.
67. Szendrei G.I., Lee V.M., Otvos L. Recognition of the minimal epitope of monoclonal antibody Tau-1 depends upon the presence of a phosphate group but not its location. J. Neurosci. Res 1993, 34:243-249.
68. Takuma H., Arawaka S., Mori H. Isoforms changes of tau protein during development in various species. Brain Res. Dev. Brain Res 2003, 142:121-127.
69. Tanemura K., Murayama M., Akagi T., Hashikawa T., Tominaga T., Ichikawa M., Yamaguchi H., Takashima A. Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J. Neurosci 2002, 22:133-141.
70. Taniguchi T., Doe N., Matsuyama S., Kitamura Y., Mori H., Saito N., Tanaka C. Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. FEBS Lett 2005, 579:5704-5712.
71. Terwel D., Lasrado R., Snauwaert J., Vandeweert E., Van Haesendonck C., Borghgraef P., Van Leuven F. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J. Biol. Chem 2005, 280:3963-3973.
72. Trinczek B., Ebneth A., Mandelkow E.M., Mandelkow E. Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles. J. Cell Sci 1999, 112:2355-2367.
73. Utton M.A., Noble W.J., Hill J.E., Anderton B.H., Hanger D.P. Molecular motors implicated in the axonal transport of tau and alpha-synuclein. J. Cell Sci 2005, 118:4645-4654.
74. Utton M.A., Vandecandelaere A., Wagner U., Reynolds C.H., Gibb G.M., Miller C.C., Bayley P.M., Anderton B.H. Phosphorylation of tau by glycogen synthase kinase 3beta affects the ability of tau to promote microtubule self-assembly. Biochem. J 1997, 323:741-747.
75. van Swieten J.C., Stevens M., Rosso S.M., Rizzu P., Joosse M., de Koning I., Kamphorst W., Ravid R., Spillantini, Niermeijer M.G., Heutink P. Phenotypic variation in hereditary frontotemporal dementia with tau mutations. Ann. Neurol 1999, 46:617-626.
76. Vershinin M., Carter B.C., Razafsky D.S., King S.J., Gross S.P. Multiple-motor based transport and its regulation by Tau. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:87-92.
77. Wolfe M.S. Tau mutations in neurodegenerative diseases. J. Biol. Chem 2009, 284:6021-6025.
78. Wrenn C.C. Social transmission of food preference in mice. Curr. Protoc. Neurosci 2004, Chapter 8, Unit 8 5G.
79. Yuan A., Kumar A., Peterhoff C., Duff K., Nixon R.A. Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J. Neurosci 2008, 28:1682-1687.
80. Zhang B., Maiti A., Shively S., Lakhani F., McDonald-Jones G., Bruce J., Lee E.B., Xie S.X., Joyce S., Li C., Toleikis P.M., Lee V.M., Trojanowski J.Q. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:227-231.